1-(2,6-dimethylphenyl)-3-{6-methoxy-7-[2-(2-methoxyethoxy)ethoxy]quinazolin-4-yl}thiourea | 320365-46-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 1-(2,6-dimethylphenyl)-3-{6-methoxy-7-[2-(2-methoxyethoxy)ethoxy]quinazolin-4-yl}thiourea
• 英文别名: 1-(2,6-Dimethylphenyl)-3-[6-methoxy-7-[2-(2-methoxyethoxy)ethoxy]quinazolin-4-yl]thiourea
• CAS: 320365-46-6
• 化学式: C₂₃H₂₈N₄O₄S
• 分子量: 456.566
• InChiKey: ZWQVFPOAWGODGK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  32
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  119
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• GUANIDINE DERIVATIVES OF QUINAZOLINE FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES
  申请人：AstraZeneca AB

  公开号：EP1296973B1

  公开（公告）日：2008-11-05
• GUANIDINE DERIVATIVES OF QUINAZOLINE AND QUINOLINE FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES
  申请人：AstraZeneca AB

  公开号：EP1296973A1

  公开（公告）日：2003-04-02
• [EN] GUANIDINE DERIVATIVES OF QUINAZOLINE AND QUINOLINE FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES<br/>[FR] DERIVES GUANIDINIQUES DE LA QUINAZOLINE ET DE LA QUINOLEINE UTILISES DANS LE TRAITEMENT DE MALADIES AUTO-IMMUNES
  申请人：ASTRAZENECA AB

  公开号：WO2002000644A1

  公开（公告）日：2002-01-03

  The invention concerns quinazoline and quinoline derivatives of Formula (I) wherein Q1 includes a quinazoline or quinoline ring optionally substituted with a group such as halogeno, trifluoromethyl and cyano, or a group of the formula: Q3 - X1 - wherein X1 includes a direct bond and O and Q3 includes aryl, aryl-(1-6C)alkyl, heterocyclyl and heterocyclyl-(1-6C)alkyl; each of R?2, R3 and R5¿ is hydrogen or (1-6C)alkyl, provides that one of the pairs of groups R?2 and R4¿ together, R?3 and R4¿ together and R?5 and R4¿ together forms a bond; R6 is an optionally substituted group selected from (2-6C) alkenyl, (2-6C) alkynyl, (3-7C)cycloalkyl and (3-7C) cycloalkenyl, or R6 is a substituted (1-6C) alkyl group; and Q2 includes aryl and aryl-(1-3C)alkyl or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the prevention or treatment of T cell mediated diseases or medical conditions in a warm-blooded animal.